Form 4: Rhythm Pharmaceuticals Executive Jennifer Kayden Lee Sells Shares to Cover Taxes and Under 10b5-1 Plan

EVP Jennifer Kayden Lee of Rhythm Pharmaceuticals sold shares of common stock on February 12th and 13th, 2025, to cover withholding taxes and under a pre-arranged 10b5-1 trading plan.

Summary

• Jennifer Kayden Lee, EVP, Head of North America at Rhythm Pharmaceuticals, sold shares of the company's common stock on February 12th and 13th, 2025.
• The sales were executed in multiple transactions at prices ranging from $56.39 to $58 per share.
• A portion of the sales was intended to cover withholding taxes related to the vesting of previously reported restricted stock units.
• The remaining sales were conducted under a Rule 10b5-1 trading plan adopted on August 8, 2024.
• Following the reported transactions, Lee directly owns 2,393 shares of Rhythm Pharmaceuticals common stock.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing detailing stock sales by an executive. It doesn't inherently convey positive or negative sentiment.

Industry Context

Executive stock sales are a common occurrence, and the use of 10b5-1 plans allows insiders to sell shares without being accused of trading on non-public information. The filing provides transparency into these transactions.

Stakeholder Impact

• The stock sales could have a minor impact on shareholders due to the increased supply of shares in the market.
• The impact is likely to be minimal as the sales were conducted under a pre-arranged trading plan and to cover tax obligations.

Key Dates